BioTuesdays

Category - Developments

3D Signatures

3DS processes first samples from PRECISE trial

3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) has processed and analyzed the first batch of blood samples for the PRECISE prostate cancer trial at its new laboratory and corporate headquarters in the MaRS Discovery...

Titan Pharmaceuticals Logo

Titan’s Probuphine featured in Fortune

The online version of Fortune magazine has produced an article about the digital health revolution that discusses the contribution of Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant as a maintenance...

antibiotic

Canadian scientists discover new antibiotic

Canadian scientists say they have discovered the first new antibiotic in three decades, and that their research suggests it may potentially be effective at killing two worrisome superbugs: Pseudomonas aeruginosa and...

ZappRx

ZappRx in $25-million Series B financing

Closely-held ZappRx closed a $25-million Series B funding led by Qiming US Healthcare Fund, with participation from SR One, which led ZappRx’s Series A round in 2014, and GV, formerly Google Ventures. ZappRx is a...

Appili Therapeutics

Appili to receive funding for new antibiotic

Closely-held Appili Therapeutics will be receiving an additional $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support development of ATI-1503, an antibiotic...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.